WinstonWınston
Back
Getinge AB (publ) logo

Getinge AB (publ)

GETI-B.ST
60
Medical - Devices · Healthcare
Exchange
Stockholm Stock Exchange
Winston Score
60
Winston is curious
A decent business — some strong pillars, some weaker.
Data as of Aug 23, 2026 · filings through Jun 30, 2026
How the score breaks down
Quality
Good
Growth
Good
Cash Flow
Strong
Stability
Strong
Valuation
Strong
Dividends
Good

Winston Score History

The full picture

Getinge is a Swedish medical technology company that makes equipment used in hospitals and life science labs. Its main products include sterilization systems, surgical tables and lights, ventilators, heart-lung machines, and intensive care equipment. Hospitals, clinics, and pharmaceutical manufacturers around the world are its primary customers.

The company earns revenue by selling capital equipment and then generating recurring income from consumables, service contracts, and software tied to that installed base. Getinge operates globally, with strong presence in Europe and North America, and reported roughly 34 billion Swedish kronor in annual sales. Its competitive position rests on long-standing customer relationships and the high cost of switching out critical hospital infrastructure once installed. The key risk facing the business is its ongoing effort to resolve past quality and regulatory issues with the U.S. Food and Drug Administration, which previously restricted some product shipments and continues to require close attention to manufacturing compliance.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
52.7%
Healthy — 52.7% gross margin
Profit after running costs
Operating Margin
16.1%
Healthy — 16.1% operating margin
Return on the money invested
ROCE
11.5%
Below par — 11.5% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-3.6%
Shrinking sales (-3.6% YoY)
Profit growth
EPS YoY
+79.8%
Earnings growing fast (+79.8% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is
EPS Consistency
5/8 quarters
Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
188%
Turns 188% of profit into real cash
Spare cash per sale
FCF Margin
11.1%
Modest free cash flow (11.1%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.31
Conservative — low debt load (0.31)
Covers its interest
Interest Cover
7.80x
Adequate interest coverage (7.8x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
24.4x
no trend
Growth-priced — P/E 24.4

P/E above the market average. People are paying up for expected growth.

Cheaper or dearer next year
P/E vs Forward
+6.7
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (24.4 → 17.7)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
1.94%
no trend
Small dividend — 1.94% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record
Dividend Growth
+89.5%
no trend
Dividend growing fast (89.5% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial